Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

nues 7,673 12,018 16,995 25,173

492,715 447,212 935,934 884,246

COSTS AND EXPENSES:

Cost of sales 101,318 83,166 191,234 169,712

Research and development 80,409 96,593 161,844 180,551

Selling, general and

administrative 209,900 189,052 408,884 341,506

Settlement reserve - 56,000 - 56,000

Restructuring charges 1,565 - 5,476 -

In-process research and

development - - 10,000 -

393,192 424,811 777,438 747,769

INCOME FROM OPERATIONS 99,523 22,401 158,496 136,477

OTHER INCOME (EXPENSE):

Interest income 4,912 8,041 11,513 14,617

Interest expense (7,872) (5,017) (16,866) (9,612)

Gain on sale of investment - 5,791 - 5,791

Other income (expense), net (1,543) (1,502) 3,772 1,254

(4,503) 7,313 (1,581) 12,050

INCOME BEFORE INCOME TAXES 95,020 29,714 156,915 148,527

INCOME TAX EXPENSE 34,952 34,022 57,996 77,650

NET INCOME (LOSS) $ 60,068 $ (4,308) $ 98,919 $ 70,877

BASIC INCOME (LOSS)

PER COMMON SHARE $0.89 $(0.06) $1.46 $1.07

DILUTED INCOME (LOSS)

PER COMMON SHARE $0.80 $(0.06) $1.33 $0.90

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 67,777 66,445 67,721 66,127

WEIGHTED AVERAGE NUMBER

OF COMMON SHARES

OUTSTANDING-ASSUMING DILUTION 74,852 66,445 74,569 78,656

CEPHALON, INC. AND SUBSIDIARIES


'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 In response to ... to address sales, training and consumer engagement challenges, ... innovative mobile applications to turn their clients’ visions ... latest customized mobile app creations, are now featured ... In partnership with Toyota, StudioPMG created a robust ...
(Date:10/1/2014)... 2014 Award winning unified communications ... four new-hosted collaboration bundles that combine next generation ... conferencing experiences for low, flat rate fees. ... businesses have optimized solutions to meet their technology ... audio only minutes (1K, 5K, 10K increments) or ...
(Date:10/1/2014)... 01, 2014 TeselaGen Biotechnology ... Foundation to expand their bioCAD/CAM software suite, which uses ... DNA. The Small Business Innovation Research Phase II grant ... under exclusive license from the Lawrence Berkeley National Laboratory. ... , an LBNL laboratory that develops alternative fuel technologies ...
(Date:10/1/2014)... LONDON, Sept. 30, 2014 This ... Enzymes in US$ Million by the following ... Specialty Enzymes. Specific end-use segments also analyzed ... The report provides separate comprehensive ... Asia-Pacific, Middle East, and Latin America. Annual ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... Trial Expected to Begin in the Second Quarter ... Mpex Pharmaceuticals, Inc. today,announced that the U.S. Food ... has granted Mpex orphan drug designation for,levofloxacin solution ... to Pseudomonas aeruginosa and other bacteria in patients,with ...
... D-Pharm announced today that,it has held its Pre-IND ... the forthcoming IND submission for DP-b99, a novel ... meeting focused on the,proposed plans for the Phase ... to date, preclinical pharmacology, toxicology data,and the FDA ...
... Dramatically Improve Airway Inflammatory Disease ... Control, NEW PROVIDENCE, N.J., March 4 Aerocrine, ... (http://www.nioxmino.com ), a,hand- held point-of-care device for the measurement ... Food and Drug Administration (FDA).,Physicians in the U.S. now ...
Cached Biology Technology:Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 3D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 4
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... 1970 and 2010 populations of mammals, birds, reptiles, ... percent, says the 2014 Living Planet Report released ... loss occurs disproportionately in low-income countriesand correlates with ... In addition to the precipitous decline in wildlife ... signs about the overall health of the planet. ...
(Date:9/29/2014)... says recently identified radiation detection properties of a light-emitting ... homeland security and medical advances. , In a paper ... Optics Letters , UT Arlington Physics Professor Wei ... fabricate transparent nanoscintillators by heating nanoparticles composed of lanthanum, ... A scintillator refers to a material that glows ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Half of global wildlife lost, says new WWF report 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... of just four factors, researchers have successfully induced ... mice to behave like embryonic stem cells. The ... publication of the journal Cell. , The cells--which ... the physical, growth, and genetic characteristics typical of ...
... by the cystic fibrosis gene has been identified by ... off the degradation system allows some proteins to regain ... aimed at curing the disease. , ... a defective gene that produces a misshapen form of ...
... Acting as a genetic Trojan horse, an experimental RNA-based drug ... into prostate cancer cells and then springs into action to ... developed at Duke University Medical Center, uses one type of ... another type, called silencing RNA, to stop the expression of ...
Cached Biology News:With few factors, adult cells take on character of embryonic stem cells 2Study reveals how cells destroy faulty proteins in cystic fibrosis 2Experimental RNA-based drug kills prostate cancer cells effectively and safely 2
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
... mutS are mismatch repair minus strains of ... repair of the newly synthesized unmethylated strand ... making them helpful in such systems as ... Systems. Both ES1301 and BMH 71-18 mutS ...
Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: